{
    "clinical_study": {
        "@rank": "80731", 
        "arm_group": [
            {
                "arm_group_label": "100 - PBO (Part1)", 
                "arm_group_type": "Experimental", 
                "description": "Participants received a single dose of 100 micrograms (mcg) subcutaneous (sc) MK-8521 in the first treatment period, and Placebo (PBO) in the second period, with a 7-day washout between each period"
            }, 
            {
                "arm_group_label": "PBO - 300 (Part 1)", 
                "arm_group_type": "Experimental", 
                "description": "Participants received a single dose sc PBO in the first treatment period, and 300 mcg MK-8521 in the second period, with a 7-day washout between each period"
            }, 
            {
                "arm_group_label": "100 - 300 (Part 1)", 
                "arm_group_type": "Experimental", 
                "description": "Participants received a single dose sc 100 mcg MK-8521 in the first treatment period, and 300 mcg MK-8521 in the second period, with a 7-day washout between each period"
            }, 
            {
                "arm_group_label": "150 - PBO - 175 (Part 1)", 
                "arm_group_type": "Experimental", 
                "description": "Participants received a single dose sc 150 mcg MK-8521 in the first treatment period, PBO in the second period, and 175 mcg MK-8521 in the third period, with a 7-day washout between each period"
            }, 
            {
                "arm_group_label": "150 - 200 - 175 (Part 1)", 
                "arm_group_type": "Experimental", 
                "description": "Participants received a single dose sc 150 mcg MK-8521 in the first treatment period, 200 mcg MK-8521 in the second period, and 175 mcg MK-8521 in the third period, with a 7-day washout between each period"
            }, 
            {
                "arm_group_label": "150 - 200 - PBO (Part 1)", 
                "arm_group_type": "Experimental", 
                "description": "Participants received a single dose sc 150 mcg MK-8521 in the first treatment period, 200 mcg MK-8521 in the second period, and PBO in the third period, with a 7-day washout between each period"
            }, 
            {
                "arm_group_label": "PBO - 200 - 175 (Part 1)", 
                "arm_group_type": "Experimental", 
                "description": "Participants received a single dose sc PBO in the first treatment period, 200 mcg MK-8521 in the second period, and 175 mcg MK-8521 in the third period, with a 7-day washout between each period"
            }, 
            {
                "arm_group_label": "50 - 74 (10 Days) (Part 2)", 
                "arm_group_type": "Experimental", 
                "description": "Once daily dose of sc MK-8521 over 10 days: 50 mcg Days 1-5, 74 mcg Days 6-10"
            }, 
            {
                "arm_group_label": "100 - 150 (10 Days) (Part 2)", 
                "arm_group_type": "Experimental", 
                "description": "Once daily dose of sc MK-8521 over 10 days: 100 mcg Days 1-5, 150 mcg Days 6-10"
            }, 
            {
                "arm_group_label": "125 - 150 (10 Days) (Part 2)", 
                "arm_group_type": "Experimental", 
                "description": "Once daily dose of sc MK-8521 over 10 days: 125 mcg Days 1-5, 150 mcg Days 6-10"
            }, 
            {
                "arm_group_label": "72 - 125 (14 Days) (Part 2)", 
                "arm_group_type": "Experimental", 
                "description": "Once daily dose of sc MK-8521 over 14 days in older and obese participants: 72 mcg Days 1-7, 125 mcg Days 8-14"
            }, 
            {
                "arm_group_label": "PBO (10 Days) (Part 2)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo for sc MK-8521 once daily over 10 days"
            }, 
            {
                "arm_group_label": "PBO (14 Days) (Part 2)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo for sc MK-8521 once daily over 14 days"
            }, 
            {
                "arm_group_label": "High-PBO-Low (Part 3)", 
                "arm_group_type": "Experimental", 
                "description": "Participants received a single dose sc high dose MK-8521 in the first treatment period, PBO in the second period, and low dose MK-8521 in the third period, with a 7-day washout between each period"
            }, 
            {
                "arm_group_label": "Low-High-PBO (Part 3)", 
                "arm_group_type": "Experimental", 
                "description": "Participants received a single dose sc low dose MK-8521 in the first treatment period, high dose MK-8521 in the second period, and PBO in the third period, with a 7-day washout between each period"
            }, 
            {
                "arm_group_label": "Low-PBO-High (Part 3)", 
                "arm_group_type": "Experimental", 
                "description": "Participants received a single dose sc low dose MK-8521 in the first treatment period, PBO in the second period, and high dose MK-8521 in the third period, with a 7-day washout between each period"
            }, 
            {
                "arm_group_label": "PBO-High-Low (Part 3)", 
                "arm_group_type": "Experimental", 
                "description": "Participants received a single dose sc PBO in the first treatment period, high dose MK-8521 in the second period, and low dose MK-8521 in the third period, with a 7-day washout between each period"
            }, 
            {
                "arm_group_label": "PBO-Low-High (Part 3)", 
                "arm_group_type": "Experimental", 
                "description": "Participants received a single dose sc PBO in the first treatment period, low dose MK-8521 in the second period, and high dose MK-8521 in the third period, with a 7-day washout between each period"
            }, 
            {
                "arm_group_label": "High-Low-PBO (Part 3)", 
                "arm_group_type": "Experimental", 
                "description": "Participants received a single dose sc high dose MK-8521 in the first treatment period, low dose MK-8521 in the second period, and PBO in the third period, with a 7-day washout between each period"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of\n      MK-8521. The primary hypothesis is that MK-8521 is sufficiently safe and well-tolerated in\n      healthy, lean and obese males."
        }, 
        "brief_title": "A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Type II Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males of either 18 to 45 or 45 to 70 years of age depending on the component of the\n             study\n\n          -  Body Mass Index between either 18-25 or 30-40 kg/m^2 depending on the component of\n             the study\n\n          -  Is in good health\n\n          -  Is a non-smoker and/or has not used nicotine for at least 3 months\n\n        Exclusion Criteria:\n\n          -  Is mentally or legally incapacitated, has significant emotional problems or has a\n             history of psychiatric disorders in the past 5 years\n\n          -  Has a history of the following abnormalities or diseases: endocrine,\n             gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal,\n             respiratory, genitourinary, or major neurological.\n\n          -  History of cancer\n\n          -  History of significant multiple or severe allergies or has had an anaphylactic\n             reaction or significant intolerability to drugs or food\n\n          -  Positive for hepatitis B surface antigen, hepatitis C antibodies or human\n             immunodeficiency virus (HIV)\n\n          -  Had major surgery, donated or lost 1 unit (500 mL) of blood or participated in\n             another study within prior 4 weeks\n\n          -  Has irritable bowel disease or recurrent nausea, vomiting, diarrhea or abdominal pain\n\n          -  History of acute or chronic pancreatitis\n\n          -  Uses 2 weeks prior to trial, or anticipates using during trial, medications, drugs or\n             herbal remedies such as St. John's Wort\n\n          -  Consumes greater than 3 glasses of alcohol per day\n\n          -  Consumes greater than 6 servings of caffeinated beverages per day\n\n          -  Regularly uses illicit drugs or has a history of drug (including alcohol)  abuse\n             within prior 3 months\n\n          -  Has known hypersensitivity to glucagon or any glucagon like peptide 1 (GLP-1)\n             receptor agonist\n\n          -  Is unwilling/unable to consume standardized meals and/or is on a carbohydrate\n             restricted diet\n\n          -  Has history of hypersensitivity to pharmacologic insulins"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "61", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02055547", 
            "org_study_id": "8521-002", 
            "secondary_id": "2013-000083-28"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "100 - PBO (Part1)", 
                    "100 - 300 (Part 1)"
                ], 
                "description": "Single dose 100 mcg sc injection in a treatment period (Part 1)", 
                "intervention_name": "MK-8521", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "150 - PBO - 175 (Part 1)", 
                    "150 - 200 - 175 (Part 1)", 
                    "150 - 200 - PBO (Part 1)"
                ], 
                "description": "Single dose 150 mcg sc injection in a treatment period (Part 1)", 
                "intervention_name": "MK-8521", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "PBO - 300 (Part 1)", 
                    "100 - 300 (Part 1)"
                ], 
                "description": "Single dose 300 mcg sc injection in a treatment period (Part 1)", 
                "intervention_name": "MK-8521", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "150 - 200 - 175 (Part 1)", 
                    "150 - 200 - PBO (Part 1)", 
                    "PBO - 200 - 175 (Part 1)"
                ], 
                "description": "Single dose 200 mcg sc injection in a treatment period (Part 1)", 
                "intervention_name": "MK-8521", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "150 - PBO - 175 (Part 1)", 
                    "150 - 200 - 175 (Part 1)", 
                    "PBO - 200 - 175 (Part 1)"
                ], 
                "description": "Single dose 175 mcg sc injection in a treatment period (Part 1)", 
                "intervention_name": "Mk-8521", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "100 - PBO (Part1)", 
                    "PBO - 300 (Part 1)", 
                    "150 - PBO - 175 (Part 1)", 
                    "150 - 200 - PBO (Part 1)", 
                    "PBO - 200 - 175 (Part 1)"
                ], 
                "description": "Single dose placebo sc injection in a treatment period (Part 1)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "50 - 74 (10 Days) (Part 2)", 
                "description": "50 mcg sc injection once each day for 5 days (Part 2)", 
                "intervention_name": "MK-8521", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "50 - 74 (10 Days) (Part 2)", 
                "description": "74 mcg sc injection once each day for 5 days (Part 2)", 
                "intervention_name": "MK-8521", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "100 - 150 (10 Days) (Part 2)", 
                "description": "100 mcg sc injection once each day for 5 days (Part 2)", 
                "intervention_name": "MK-8521", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "125 - 150 (10 Days) (Part 2)", 
                "description": "125 mcg sc injection once each day for 5 days (Part 2)", 
                "intervention_name": "MK-8521", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "100 - 150 (10 Days) (Part 2)", 
                    "125 - 150 (10 Days) (Part 2)"
                ], 
                "description": "150 mcg sc injection once each day for 5 days (Part 2)", 
                "intervention_name": "MK-8521", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "72 - 125 (14 Days) (Part 2)", 
                "description": "72 mcg sc injection once each day for 7 days (Part 2)", 
                "intervention_name": "MK-8521", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "72 - 125 (14 Days) (Part 2)", 
                "description": "125 mcg sc injection once each day for 7 days (Part 2)", 
                "intervention_name": "MK-8521", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PBO (10 Days) (Part 2)", 
                "description": "Placebo sc injection once each day for 10 days (Part 2)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PBO (14 Days) (Part 2)", 
                "description": "Placebo sc injection once each day for 14 days (Part 2)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "High-PBO-Low (Part 3)", 
                    "Low-High-PBO (Part 3)", 
                    "Low-PBO-High (Part 3)", 
                    "PBO-High-Low (Part 3)", 
                    "PBO-Low-High (Part 3)", 
                    "High-Low-PBO (Part 3)"
                ], 
                "description": "Single low dose sc injection in a treatment period (Part 3)", 
                "intervention_name": "MK-8521", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "High-PBO-Low (Part 3)", 
                    "Low-High-PBO (Part 3)", 
                    "Low-PBO-High (Part 3)", 
                    "PBO-High-Low (Part 3)", 
                    "PBO-Low-High (Part 3)", 
                    "High-Low-PBO (Part 3)"
                ], 
                "description": "Single high dose sc injection in a treatment period (Part 3)", 
                "intervention_name": "MK-8521", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "High-PBO-Low (Part 3)", 
                    "Low-High-PBO (Part 3)", 
                    "Low-PBO-High (Part 3)", 
                    "PBO-High-Low (Part 3)", 
                    "PBO-Low-High (Part 3)", 
                    "High-Low-PBO (Part 3)"
                ], 
                "description": "Single Placebo sc injection in a treatment period (Part 3)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Antwerpen", 
                    "country": "Belgium"
                }, 
                "name": "SGS Life Science Services"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "19", 
        "official_title": "A Single and Multiple-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8521 in Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: FAMHP (Federal Agency for Medicines and Health Products)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of participants with an adverse event (AE) (Part 1)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 34"
            }, 
            {
                "measure": "Number of participants who discontinued treatment due to an AE (Part 1)", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Area under the curve (AUC) 0-\u221e for plasma concentration of participants treated with a single dose of MK-8521 (Part 1)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 6"
            }, 
            {
                "measure": "Peak plasma concentration (Cmax) of participants treated with a single dose of MK-8521 (Part 1)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 6"
            }, 
            {
                "measure": "Time taken to reach Cmax (Tmax) for plasma concentration of participants treated with a single dose of MK-8521 (Part 1)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 6"
            }, 
            {
                "measure": "Apparent terminal half-life (T 1/2) for plasma concentration of participants treated with a single dose of MK-8521 (Part 1)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 6"
            }, 
            {
                "measure": "Number of participants with an AE (Part 2)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 43"
            }, 
            {
                "measure": "Number of participants who discontinued treatment due to an AE (Part 2)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 14"
            }, 
            {
                "measure": "AUC 0-24hr for plasma concentration of participants treated with multiple doses of MK-8521 (Part 2)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 19"
            }, 
            {
                "measure": "Cmax for plasma concentration of participants treated with multiple doses of MK-8521(Part 2)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 19"
            }, 
            {
                "measure": "Trough plasma concentration (Ctrough) of participants treated with multiple doses of MK-8521(Part 2)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 19"
            }, 
            {
                "measure": "Tmax for plasma concentration of participants treated with multiple doses of MK-8521 (Part 2)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 19"
            }, 
            {
                "measure": "T 1/2 for plasma concentration of participants treated with multiple doses of MK-8521 (Part 2)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 19"
            }, 
            {
                "measure": "Number of participants with an AE (Part 3)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 43"
            }, 
            {
                "measure": "Number of participants who discontinued treatment due to an AE (Part 3)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 14"
            }, 
            {
                "measure": "Slope of insulin secretion rate/glucose (ISR/G) during graded glucose infusion (GGI) due to treatment with a single dose of MK-8521 (Part 3)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02055547"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in time-weighted average (TWA) 0-24 hrs heart rate of participants treated with a single dose of MK-8521 (Part 1)", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 pre-dose and through Day 2 after dosing"
            }, 
            {
                "measure": "Change from baseline in TWA 0-24 hrs systolic blood pressure (BP) of participants treated with a single dose of MK-8521 (Part 1)", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 pre-dose and through Day 2 after dosing"
            }, 
            {
                "measure": "Change from baseline in TWA 0-24 hrs diastoliic BP of participants treated with a single dose of MK-8521 (Part 1)", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 pre-dose and through Day 2 after dosing"
            }, 
            {
                "measure": "Change from baseline in TWA 0-24 hrs heart rate of participants treated with multiple doses of MK-8521 (Part 2)", 
                "safety_issue": "Yes", 
                "time_frame": "Day (-1) and up to Day 14"
            }, 
            {
                "measure": "Change from baseline in TWA 0-24 hrs systolic BP of participants treated with multiple doses of MK-8521 (Part 2)", 
                "safety_issue": "Yes", 
                "time_frame": "Day (-1) and up to Day 14"
            }, 
            {
                "measure": "Change from baseline in TWA 0-24 hrs diastolic BP of participants treated with multiple doses of MK-8521 (Part 2)", 
                "safety_issue": "Yes", 
                "time_frame": "Day (-1) and up to Day 14"
            }, 
            {
                "measure": "Glucose (TWA 0-160 min) during GGI at Tmax due to treatment with a single dose of MK-8521 (Part 3)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Maximum glycemic excursion (Gmax) during GGI at Tmax due to treatment with a single dose of MK-8521 (Part 3)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Ratio of ISR/G at the highest glucose infusion rate during GGI due to treatment with a single dose  of MK-8521 (Part 3)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "AUC 0-\u221e for plasma concentration of participants treated with a single dose of MK-8521 (Part 3)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Cmax for plasma concentration of participants treated with a single dose of MK-8521 (Part 3)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Tmax for plasma concentration of participants treated with a single dose of MK-8521 (Part 3)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "T 1/2 for plasma concentration of participants treated with a single dose of MK-8521 (Part 3)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Slope of (ISR/G) during GGI at Tmax due to treatment with a single dose of MK-8521 (Part 3)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}